Chauche Thierry reported grant involving 50,000 derivative units of Sagimet Biosciences Inc. at $0.00 for $0 on May 28, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Jun 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
50,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
50,000Direct
Trade date
May 28, 2026Grant
Filed
Jun 1, 2026, 9:16 PM ET5-day reporting delay
Accession
0001104659-26-069124Code A · Transaction 388485
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SGMT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SGMT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +29%1w ago +3.1%1d ago +6.3%
Returns since7d −4%30d +12%90d +51%180d1y

Footnotes in full

F1: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.